The Vaccine Scaling Problem
A couple of weeks back, the CEO of Serum Institute of India announced that the launch of a new Covid-19 vaccine Covovax developed jointly in association with Novavax is likely to be delayed to September in the country. This came against the backdrop of a US Ban on exports of key raw materials required to manufacture…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Finshots Daily →
Vaccinating a Billion Indians
India’s CDMO surge: The business behind the Drugs
Fewer COVID Vaccine Doses Materialized Last Fall Than The U.S. Government Hoped
Why Indian Pharma struggles with quality control
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.